Daniel Gliddon

479 total citations
15 papers, 309 citations indexed

About

Daniel Gliddon is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel Gliddon has authored 15 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Immunology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel Gliddon's work include Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Daniel Gliddon is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Daniel Gliddon collaborates with scholars based in United Kingdom, United States and Canada. Daniel Gliddon's co-authors include Jayne C. Hope, Christopher J. Howard, Neil Brewis, Alexander Koers, Sarah Batey, Michelle Morrow, Matthew Kraman, Mustapha Faroudi, Mateusz Wydro and Jacqueline Doody and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Cancer Research.

In The Last Decade

Daniel Gliddon

14 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Gliddon United Kingdom 8 209 166 70 55 16 15 309
Iva Zlatareva United Kingdom 7 402 1.9× 152 0.9× 34 0.5× 63 1.1× 5 0.3× 8 483
Xavier Y.X. Sng Australia 7 324 1.6× 101 0.6× 29 0.4× 137 2.5× 5 0.3× 10 443
Elizabeth Feo Figarella United States 6 349 1.7× 76 0.5× 75 1.1× 84 1.5× 16 1.0× 6 443
Thomas Mørch Frøsig Denmark 9 229 1.1× 144 0.9× 17 0.2× 90 1.6× 3 0.2× 12 318
Jean Caraux France 11 162 0.8× 49 0.3× 78 1.1× 85 1.5× 4 0.3× 28 289
Alok V. Joglekar United States 7 244 1.2× 156 0.9× 73 1.0× 156 2.8× 8 344
R. Andres Parra Sperberg United States 7 139 0.7× 127 0.8× 33 0.5× 160 2.9× 1 0.1× 9 316
John K. Northrop United States 5 456 2.2× 100 0.6× 24 0.3× 90 1.6× 2 0.1× 6 546
Pengfei Zhou China 8 175 0.8× 101 0.6× 22 0.3× 130 2.4× 18 361
Regula B. Buser Switzerland 7 99 0.5× 46 0.3× 144 2.1× 141 2.6× 3 0.2× 7 336

Countries citing papers authored by Daniel Gliddon

Since Specialization
Citations

This map shows the geographic impact of Daniel Gliddon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Gliddon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Gliddon more than expected).

Fields of papers citing papers by Daniel Gliddon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Gliddon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Gliddon. The network helps show where Daniel Gliddon may publish in the future.

Co-authorship network of co-authors of Daniel Gliddon

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Gliddon. A scholar is included among the top collaborators of Daniel Gliddon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Gliddon. Daniel Gliddon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Kraman, Matthew, Mustapha Faroudi, Daniel Gliddon, et al.. (2020). FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. Clinical Cancer Research. 26(13). 3333–3344. 82 indexed citations
2.
Lakins, Matthew A., Alexander Koers, Jose Muñoz-Olaya, et al.. (2020). FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models. Clinical Cancer Research. 26(15). 4154–4167. 44 indexed citations
3.
Yap, Timothy A., Siwen Hu‐Lieskovan, Kyriakos P. Papadopoulos, et al.. (2020). 395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy. Regular and Young Investigator Award Abstracts. A240–A240. 11 indexed citations
4.
5.
Lakins, Matthew A., Alexander Koers, Robert Hughes, et al.. (2020). Abstract 4547: Clustering CD137 via cell-expressed PD-L1 crosslinking avoided Fc-mediated agonism and resulted in safe and potent conditional lymphocyte activation. Cancer Research. 80(16_Supplement). 4547–4547. 1 indexed citations
6.
Faroudi, Mustapha, Matthew Kraman, Daniel Gliddon, et al.. (2019). Abstract 2399: LAG-3/PD-L1 mAb2 can overcome PD-L1-mediated compensatory upregulation of LAG-3 induced by single-agent checkpoint blockade. Cancer Research. 79(13_Supplement). 2399–2399. 2 indexed citations
7.
Lakins, Matthew A., Alexander Koers, D. H. Jones, et al.. (2019). Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile. Immunology. 1540–1540. 1 indexed citations
8.
Lakins, Matthew A., Alexander Koers, Daniel B. Jones, et al.. (2019). Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile. Cancer Research. 79(13_Supplement). 1540–1540. 1 indexed citations
9.
Kraman, Matthew, Katy L. Everett, Mustapha Faroudi, et al.. (2018). Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses. Cancer Research. 78(13_Supplement). 2719–2719. 13 indexed citations
10.
Singh, Amrit, Casey P. Shannon, Jenny Thiele, et al.. (2017). Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge. The Journal of Immunology. 199(10). 3395–3405. 3 indexed citations
11.
Grimaldi, Christine, Deborah Finco, Madeline Fort, et al.. (2016). Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine. 85. 101–108. 32 indexed citations
12.
Kirton, Christopher M., et al.. (2011). In Vitro Cytokine Release Assays: Reducing The Risk of Adverse Events in Man. Bioanalysis. 3(23). 2657–2663. 3 indexed citations
13.
Gliddon, Daniel, et al.. (2004). DEC‐205 expression on migrating dendritic cells in afferent lymph. Immunology. 111(3). 262–272. 62 indexed citations
14.
Gliddon, Daniel, et al.. (2002). CD26 is expressed on a restricted subpopulation of dendritic cells in vivo. European Journal of Immunology. 32(5). 1472–1472. 40 indexed citations
15.
Howard, C.J., et al.. (2002). Co-stimulation and modulation of the ensuing immune response. Veterinary Immunology and Immunopathology. 87(3-4). 123–130. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Iva Zlatareva Breakdown of academic impact, for papers by Xavier Y.X. Sng Breakdown of academic impact, for papers by Elizabeth Feo Figarella Breakdown of academic impact, for papers by Thomas Mørch Frøsig Breakdown of academic impact, for papers by Jean Caraux Breakdown of academic impact, for papers by Alok V. Joglekar Breakdown of academic impact, for papers by R. Andres Parra Sperberg Breakdown of academic impact, for papers by John K. Northrop Breakdown of academic impact, for papers by Pengfei Zhou Breakdown of academic impact, for papers by Regula B. Buser
Rankless by CCL
2026